Nose-Based Vaccine Offers New Hope Against Tuberculosis
Photo: CDC / Unsplash
Researchers at Johns Hopkins Medicine are pioneering a nasal vaccine that targets tuberculosis through an innovative DNA approach, designed to combat drug-resistant strains of the disease. By combining two tuberculosis genes, the vaccine aims to train the immune system to eliminate bacteria that can survive standard antibiotic treatment. This breakthrough could transform how we prevent and treat tuberculosis, which remains the world's deadliest infectious disease.
Researchers at Johns Hopkins Medicine are pioneering a nasal vaccine that targets tuberculosis through an innovative DNA approach, designed to combat drug-resistant strains of the disease. By combining two tuberculosis genes, the vaccine aims to train the immune system to eliminate bacteria that can survive standard antibiotic treatment. This breakthrough could transform how we prevent and treat tuberculosis, which remains the world’s deadliest infectious disease.